603983 丸美生物
已收盘 12-16 15:00:00
资讯
新帖
简况
港股IPO监管升级，丸美生物能否越过“财务问题”门槛成功上市？
市场资讯 · 12-15 00:00
港股IPO监管升级，丸美生物能否越过“财务问题”门槛成功上市？
新股消息 | 丸美生物(603983.SH)递表港交所
智通财经 · 12-12
新股消息 | 丸美生物(603983.SH)递表港交所
屈臣氏拟明年于香港伦敦双重上市
山东商报 · 12-02
屈臣氏拟明年于香港伦敦双重上市
丸美生物（603983）披露拟首次公开发行H股并在港交所上市，12月1日股价上涨0.11%
证券之星 · 12-01
丸美生物（603983）披露拟首次公开发行H股并在港交所上市，12月1日股价上涨0.11%
11月25日丸美生物涨5.08%，富国消费主题混合A基金重仓该股
证券之星 · 11-25
11月25日丸美生物涨5.08%，富国消费主题混合A基金重仓该股
丸美生物涨5.08%，开源证券三周前给出“买入”评级
证券之星 · 11-25
丸美生物涨5.08%，开源证券三周前给出“买入”评级
账上15亿，分红超10亿，丸美生物为何仍要赴港融资？
市场资讯 · 11-17
账上15亿，分红超10亿，丸美生物为何仍要赴港融资？
每周股票复盘：XD丸美生（603983）丸美生物拟发行H股并延期募投项目
证券之星 · 11-16
每周股票复盘：XD丸美生（603983）丸美生物拟发行H股并延期募投项目
丸美生物(603983.SH)筹划发行H股股票并申请在香港联交所上市
智通财经 · 11-12
丸美生物(603983.SH)筹划发行H股股票并申请在香港联交所上市
每周股票复盘：丸美生物（603983）丸美自播业务三季度增长100%
证券之星 · 11-09
每周股票复盘：丸美生物（603983）丸美自播业务三季度增长100%
【机构调研记录】工银瑞信基金调研丸美生物、西南证券等3只个股（附名单）
证券之星 · 11-04
【机构调研记录】工银瑞信基金调研丸美生物、西南证券等3只个股（附名单）
每周股票复盘：丸美生物（603983）Q3净利下滑38.83%
证券之星 · 11-02
每周股票复盘：丸美生物（603983）Q3净利下滑38.83%
丸美生物（603983）2025年三季报简析：营收净利润同比双双增长
证券之星 · 11-01
丸美生物（603983）2025年三季报简析：营收净利润同比双双增长
丸美生物(603983)9月30日股东户数1.89万户，较上期增加8.86%
证券之星 · 10-31
丸美生物(603983)9月30日股东户数1.89万户，较上期增加8.86%
图解丸美生物三季报：第三季度单季净利润同比下降6.61%
证券之星 · 10-31
图解丸美生物三季报：第三季度单季净利润同比下降6.61%
丸美生物因未及时披露公司重大事件等违规行为被证监会责令改正
证券之星 · 10-31
丸美生物因未及时披露公司重大事件等违规行为被证监会责令改正
丸美生物（603983）披露公司2025年半年度利润分配方案，9月19日股价下跌1.13%
证券之星 · 09-19
丸美生物（603983）披露公司2025年半年度利润分配方案，9月19日股价下跌1.13%
每周股票复盘：丸美生物（603983）每10股派2.5元含税红利
证券之星 · 09-14
每周股票复盘：丸美生物（603983）每10股派2.5元含税红利
丸美生物（603983）披露利润分配方案公告，9月12日股价上涨1.07%
证券之星 · 09-12
丸美生物（603983）披露利润分配方案公告，9月12日股价上涨1.07%
每周股票复盘：丸美生物（603983）召开临时股东大会并变更办公地址
证券之星 · 09-07
每周股票复盘：丸美生物（603983）召开临时股东大会并变更办公地址
暂无数据
公司概况
公司名称：
广东丸美生物技术股份有限公司
所属行业：
化学原料和化学制品制造业
上市日期：
2019-07-25
主营业务：
广东丸美生物技术股份有限公司的主营业务是化妆品的研发、设计、生产、销售及服务。公司的主要产品是眼部类、护肤类、洁肤类、美容及其他类。公司关键技术“重组胶原蛋白高效嵌合表达及抗衰研究”荣膺IFSCC“2025中国化妆品技术创新奖”。
发行价格：
20.54
{"stockData":{"symbol":"603983","market":"SH","secType":"STK","nameCN":"丸美生物","latestPrice":33.16,"timestamp":1765868400000,"preClose":33.18,"halted":0,"volume":1360800,"delay":0,"changeRate":-0.0006,"floatShares":401000000,"shares":401000000,"eps":0.8647,"marketStatus":"已收盘","change":-0.02,"latestTime":"12-16 15:00:00","open":33.16,"high":33.56,"low":32.91,"amount":45208200,"amplitude":0.0196,"askPrice":33.19,"askSize":1,"bidPrice":33.16,"bidSize":8,"shortable":0,"etf":0,"ttmEps":0.8647,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765935000000},"marketStatusCode":5,"adr":0,"adjPreClose":33.18,"symbolType":"stock","openAndCloseTimeList":[[1765848600000,1765855800000],[1765861200000,1765868400000]],"highLimit":36.5,"lowLimit":29.86,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":401000000,"isCdr":false,"pbRate":4,"roa":"--","peRate":38.34856,"roe":"7.17%","epsLYR":0.85,"committee":-0.235955,"marketValue":13297000000,"turnoverRate":0.0034,"status":1,"floatMarketCap":13297000000},"requestUrl":"/m/hq/s/603983/tweets","defaultTab":"tweets","newsList":[{"id":"2591695848","title":"港股IPO监管升级，丸美生物能否越过“财务问题”门槛成功上市？","url":"https://stock-news.laohu8.com/highlight/detail?id=2591695848","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591695848?lang=zh_cn&edition=full","pubTime":"2025-12-15 00:00","pubTimestamp":1765728000,"startTime":"0","endTime":"0","summary":" 近日，香港证监会与港交所罕见地联名致函所有保荐机构，直指当前港股IPO申请材料质量下滑、不合规行为增多。今年截至11月底，港股IPO募资额已飙至2594亿港元，同比激增2.28倍，创四年新高。 如今转向港股，在监管对材料质量和信息披露要求显著提升的背景下，丸美生物能否彻底厘清历史财务问题，跨越这道关键的合规门槛，成为其上市成败的关键一环。值得留意的是，2023年及2024年，丸美生物分红比例均超过80%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggipo/2025-12-15/doc-inhavwnp4255565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603983","BK0229"],"gpt_icon":0},{"id":"2590542059","title":"新股消息 | 丸美生物(603983.SH)递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2590542059","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590542059?lang=zh_cn&edition=full","pubTime":"2025-12-12 06:19","pubTimestamp":1765491549,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所12月11日披露，广东丸美生物技术股份有限公司(603983.SH)向港交所主板递交上市申请，高盛、中信证券为其联席保荐人。招股书显示，丸美生物是专注于为消费者提供抗衰解决方案的中国领先美妆企业。公司以合成生物学技术驱动，深耕抗衰护肤品行业二十余年，不断通过专注于研发及以重组胶原蛋白为代表的核心技术突破，将前沿科技创新应用到具有抗皱、紧致和修护等功效的护肤产品中。基于弗若斯特沙利文报告，以2024年零售额计，丸美生物是重组胶原蛋白护肤品细分领域的中国第三大美妆企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603983","BK0229","HEXmain"],"gpt_icon":0},{"id":"2588009817","title":"屈臣氏拟明年于香港伦敦双重上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2588009817","media":"山东商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588009817?lang=zh_cn&edition=full","pubTime":"2025-12-02 09:43","pubTimestamp":1764639780,"startTime":"0","endTime":"0","summary":"商报消息 日前，据《华尔街日报》等媒体援引知情人士消息，李嘉诚旗下长江和记实业有限公司（00001.HK，下称“长和”）旗下的屈臣氏集团正计划在中国香港、英国伦敦双重上市。若此次上市进 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251202/c672887543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["603983","BK0217","LU1997245094.SGD","IE0005HP3H50.USD","BK0229","003010","LU1820825898.SGD","LU1146622755.USD","603605","LU1997245177.USD","LU2460026573.USD","LU0593848301.USD"],"gpt_icon":0},{"id":"2588093725","title":"丸美生物（603983）披露拟首次公开发行H股并在港交所上市，12月1日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588093725","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588093725?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:55","pubTimestamp":1764582933,"startTime":"0","endTime":"0","summary":"根据近日发布的公告，广东丸美生物技术股份有限公司于2025年11月28日召开2025年第二次临时股东大会，会议审议通过了关于公司首次公开发行H股股票并在香港联合交易所上市的相关议案，包括发行方案、募集资金使用计划、转为境外募集股份有限公司、授权董事会办理上市事宜等。同时，会议还审议通过了取消监事会并修订公司章程、选举第五届董事会独立董事、制定H股上市后适用的公司章程（草案）及多项内部治理制度修订议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100023701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","HEXmain","603983"],"gpt_icon":0},{"id":"2586040442","title":"11月25日丸美生物涨5.08%，富国消费主题混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586040442","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586040442?lang=zh_cn&edition=full","pubTime":"2025-11-25 15:33","pubTimestamp":1764055984,"startTime":"0","endTime":"0","summary":"证券之星消息，11月25日丸美生物涨5.08%创60日新低，收盘报34.57元，换手率1.83%，成交量7.33万手，成交额2.51亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为富国基金的富国消费主题混合A。富国消费主题混合A目前规模为31.65亿元，最新净值2.22，较上一交易日下跌0.76%，近一年上涨2.92%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500017324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","603983"],"gpt_icon":0},{"id":"2586805447","title":"丸美生物涨5.08%，开源证券三周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2586805447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586805447?lang=zh_cn&edition=full","pubTime":"2025-11-25 15:32","pubTimestamp":1764055975,"startTime":"0","endTime":"0","summary":"今日丸美生物涨5.08%，收盘报34.57元。2025年11月2日，开源证券研究员黄泽鹏,李昕恬发布了对丸美生物的研报《公司信息更新报告：2025Q3业绩亮眼，多赛道布局有望驱动业绩增长》，该研报对丸美生物给出“买入”评级。研报中预计公司2025-2027年归母净利润为4.00/5.23/6.67亿元，对应EPS为1.00/1.30/1.66元，当前股价对应PE为34.6/26.5/20.8倍，维持“买入”评级。此外，东吴证券研究员吴劲草,郗越，华源证券研究员丁一近期也对该股发布了研报，同样给出“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500017319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","603983"],"gpt_icon":0},{"id":"2584320614","title":"账上15亿，分红超10亿，丸美生物为何仍要赴港融资？","url":"https://stock-news.laohu8.com/highlight/detail?id=2584320614","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584320614?lang=zh_cn&edition=full","pubTime":"2025-11-17 13:41","pubTimestamp":1763358060,"startTime":"0","endTime":"0","summary":" 丸美生物正计划在资本市场上完成一次新的“图谋”。 在登陆A股六年后，丸美生物于11月12日正式宣布拟发行H股股票，意欲搭建“A+H”双资本平台。该项目历经多次变更，并在2023年与2024年两度延期后，于宣布赴港上市的同日，再次决定延期两年。截至三季度末，丸美生物账上货币资金高达15.92亿元，交易性金融资产达4.13亿元，且经营活动现金流同比激增132.19%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2025-11-17/doc-infxsxya6444458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0229","603983"],"gpt_icon":0},{"id":"2583654856","title":"每周股票复盘：XD丸美生（603983）丸美生物拟发行H股并延期募投项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2583654856","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583654856?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:18","pubTimestamp":1763237891,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，XD丸美生报收于33.45元，较上周的33.56元下跌0.33%。本周，XD丸美生11月14日盘中最高价报34.77元。XD丸美生当前最新总市值134.13亿元，在化妆品板块市值排名4/14，在两市A股市值排名1433/5165。本周关注点公司公告汇总：丸美生物拟发行H股并在港交所主板上市，相关议案已获董事会审议通过。监事会及保荐人中信证券对该延期事项无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603983","BK0229"],"gpt_icon":0},{"id":"2582221253","title":"丸美生物(603983.SH)筹划发行H股股票并申请在香港联交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2582221253","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582221253?lang=zh_cn&edition=full","pubTime":"2025-11-12 18:21","pubTimestamp":1762942904,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丸美生物(603983.SH)发布公告，为增强公司资本实力与境外融资能力，进一步提高公司的综合竞争力，加快公司业务的国际化战略，根据公司总体发展战略及运营需要，公司拟发行H股股票并申请在香港联合交易所有限公司(简称“香港联交所”)主板挂牌上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368376.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"丸美生物(603983.SH)筹划发行H股股票并申请在香港联交所上市","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0229","603983"],"gpt_icon":0},{"id":"2582861415","title":"每周股票复盘：丸美生物（603983）丸美自播业务三季度增长100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582861415","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582861415?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:10","pubTimestamp":1762632625,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，丸美生物报收于33.56元，较上周的34.53元下跌2.81%。本周，丸美生物11月3日盘中最高价报34.76元。丸美生物当前最新总市值134.58亿元，在化妆品板块市值排名4/14，在两市A股市值排名1430/5166。本周关注点来自机构调研要点：丸美自播业务三季度实现100%增长。公司公告汇总丸美生物2025年半年度权益分派方案已获通过，以总股本401,000,000股为基数，每股派发现金红利0.25元（含税），合计派发100,250,000.00元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603983","BK0229"],"gpt_icon":0},{"id":"2580227052","title":"【机构调研记录】工银瑞信基金调研丸美生物、西南证券等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2580227052","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580227052?lang=zh_cn&edition=full","pubTime":"2025-11-04 08:06","pubTimestamp":1762214777,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月3日披露的机构调研信息，工银瑞信基金近期对3家上市公司进行了调研，相关名单如下：1）丸美生物 调研纪要：三季度自播业务实现100%增长，得益于产品换新、主播迭代、内容加强、组织变革和人群资产积累。公司为银华基金第一大股东，规范行使股东权利，获稳定回报。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400005748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0229","BK0276","603983","BK0188","BK0012","600369","BK0028"],"gpt_icon":0},{"id":"2580102477","title":"每周股票复盘：丸美生物（603983）Q3净利下滑38.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580102477","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580102477?lang=zh_cn&edition=full","pubTime":"2025-11-02 07:38","pubTimestamp":1762040293,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，丸美生物报收于34.53元，较上周的35.76元下跌3.44%。本周，丸美生物10月30日盘中最高价报37.03元。业绩披露要点2025年前三季度，丸美生物实现营业收入24.50亿元，同比增长25.51%；归母净利润2.44亿元，同比增长2.13%；扣非净利润2.14亿元，同比下降5.42%。2025年第三季度单季，营业收入6.81亿元，同比增长13.52%；归母净利润5815.2万元，同比下降6.61%；扣非净利润3669.61万元，同比下降38.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","603983"],"gpt_icon":0},{"id":"2580041214","title":"丸美生物（603983）2025年三季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2580041214","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580041214?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:29","pubTimestamp":1761949761,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期丸美生物发布2025年三季报。根据财报显示，丸美生物营收净利润同比双双增长。截至本报告期末，公司营业总收入24.5亿元，同比上升25.51%，归母净利润2.44亿元，同比上升2.13%。按单季度数据看，第三季度营业总收入6.86亿元，同比上升14.28%，第三季度归母净利润6948.16万元，同比上升11.59%。持有丸美生物最多的基金为富国消费主题混合A，目前规模为31.65亿元，最新净值2.315，较上一交易日下跌0.43%，近一年上涨3.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100006270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603983"],"gpt_icon":0},{"id":"2579451580","title":"丸美生物(603983)9月30日股东户数1.89万户，较上期增加8.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579451580","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579451580?lang=zh_cn&edition=full","pubTime":"2025-10-31 17:31","pubTimestamp":1761903102,"startTime":"0","endTime":"0","summary":"证券之星消息，近日丸美生物披露，截至2025年9月30日公司股东户数为1.89万户，较6月30日增加1539.0户，增幅为8.86%。在化妆品行业个股中，丸美生物股东户数低于行业平均水平，截至9月30日，化妆品行业平均股东户数为3.17万户。从股价来看，2025年6月30日至2025年9月30日，丸美生物区间跌幅为5.53%，在此期间股东户数增加1539.0户，增幅为8.86%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100036671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603983","BK0229"],"gpt_icon":0},{"id":"2579175223","title":"图解丸美生物三季报：第三季度单季净利润同比下降6.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579175223","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579175223?lang=zh_cn&edition=full","pubTime":"2025-10-31 02:51","pubTimestamp":1761850312,"startTime":"0","endTime":"0","summary":"证券之星消息，丸美生物2025年三季报显示，前三季度公司主营收入24.5亿元，同比上升25.51%；归母净利润2.44亿元，同比上升2.13%；扣非净利润2.14亿元，同比下降5.42%；其中2025年第三季度，公司单季度主营收入6.81亿元，同比上升13.52%；单季度归母净利润5815.2万元，同比下降6.61%；单季度扣非净利润3669.61万元，同比下降38.83%；负债率30.03%，投资收益1682.37万元，财务费用-1589.43万元，毛利率74.91%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100003080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603983"],"gpt_icon":0},{"id":"2579120313","title":"丸美生物因未及时披露公司重大事件等违规行为被证监会责令改正","url":"https://stock-news.laohu8.com/highlight/detail?id=2579120313","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579120313?lang=zh_cn&edition=full","pubTime":"2025-10-31 01:00","pubTimestamp":1761843651,"startTime":"0","endTime":"0","summary":"证券之星消息，10月31日丸美生物公开信息显示，广东丸美生物技术股份有限公司，董事长孙怀庆、董事王开慧、董事会秘书程迪因未及时披露公司重大事件,未依法履行其他职责,信息披露违规被中国证券监督管理委员会广东监管局责令改正。二是募投项目调整未及时审议和披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100002200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","603983"],"gpt_icon":0},{"id":"2568261608","title":"丸美生物（603983）披露公司2025年半年度利润分配方案，9月19日股价下跌1.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568261608","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568261608?lang=zh_cn&edition=full","pubTime":"2025-09-19 22:38","pubTimestamp":1758292706,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘，丸美生物报收于39.45元，较前一交易日下跌1.13%，最新总市值为158.19亿元。近日，广东丸美生物技术股份有限公司召开2025年第一次临时股东大会，审议通过《公司2025年半年度利润分配方案》。公告显示，出席会议的股东及代理人共238人，代表有表决权股份总数331,865,352股，占公司有表决权股份总数的82.7594%。中小股东对该议案的同意票数为7,739,551股，占出席本次会议中小股东有效表决权股份的98.4005%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091900037438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","603983"],"gpt_icon":0},{"id":"2567613572","title":"每周股票复盘：丸美生物（603983）每10股派2.5元含税红利","url":"https://stock-news.laohu8.com/highlight/detail?id=2567613572","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567613572?lang=zh_cn&edition=full","pubTime":"2025-09-14 04:16","pubTimestamp":1757794573,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，丸美生物报收于40.5元，较上周的41.02元下跌1.27%。本周，丸美生物9月8日盘中最高价报41.77元。丸美生物当前最新总市值162.53亿元，在化妆品板块市值排名4/14，在两市A股市值排名1171/5153。如股权登记日前总股本变动，将维持每股分配比例不变，相应调整分配总额。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400000956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603983","BK0229"],"gpt_icon":0},{"id":"2566708589","title":"丸美生物（603983）披露利润分配方案公告，9月12日股价上涨1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566708589","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566708589?lang=zh_cn&edition=full","pubTime":"2025-09-12 22:32","pubTimestamp":1757687563,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，丸美生物报收于40.5元，较前一交易日上涨1.07%，最新总市值为162.4亿元。该股当日开盘40.0元，最高40.84元，最低39.81元，成交额达1.06亿元，换手率为0.65%。会议将审议《公司2025年半年度利润分配方案》。截至2025年6月30日，公司母公司报表未分配利润为1,517,786,571.38元。如股权登记日前总股本发生变动，公司将维持每股分配比例不变，相应调整分配总额。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091200038529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603983","BK0229"],"gpt_icon":0},{"id":"2565709545","title":"每周股票复盘：丸美生物（603983）召开临时股东大会并变更办公地址","url":"https://stock-news.laohu8.com/highlight/detail?id=2565709545","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565709545?lang=zh_cn&edition=full","pubTime":"2025-09-07 07:00","pubTimestamp":1757199635,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘，丸美生物报收于41.02元，较上周的40.75元上涨0.66%。本周关注点公司公告汇总：丸美生物将于2025年9月19日召开2025年第一次临时股东大会，审议半年度利润分配方案。公司公告汇总：丸美生物办公地址变更为广州市海珠区新港东路69号丸美大厦11楼。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090700001484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603983","BK0229"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765886061959,"stockEarnings":[{"period":"1week","weight":-0.0476},{"period":"1month","weight":-0.0081},{"period":"3month","weight":-0.1641},{"period":"6month","weight":-0.1953},{"period":"1year","weight":0.0423},{"period":"ytd","weight":0.0475}],"compareEarnings":[{"period":"1week","weight":-0.0143},{"period":"1month","weight":-0.0307},{"period":"3month","weight":0.0016},{"period":"6month","weight":0.1414},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.154}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东丸美生物技术股份有限公司","boardCode":"AI0026","boardName":"化学原料和化学制品制造业","stockholders":"18910人(较上一季度增加8.86%)","perCapita":"21205股","listingDate":"2019-07-25","address":"广东省广州市黄埔区高新技术产业开发区科学城伴河路92号2号楼","registeredCapital":"40100万元","survey":" 广东丸美生物技术股份有限公司的主营业务是化妆品的研发、设计、生产、销售及服务。公司的主要产品是眼部类、护肤类、洁肤类、美容及其他类。公司关键技术“重组胶原蛋白高效嵌合表达及抗衰研究”荣膺IFSCC“2025中国化妆品技术创新奖”。","listedPrice":20.54},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丸美生物(603983)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丸美生物(603983)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丸美生物,603983,丸美生物股票,丸美生物股票老虎,丸美生物股票老虎国际,丸美生物行情,丸美生物股票行情,丸美生物股价,丸美生物股市,丸美生物股票价格,丸美生物股票交易,丸美生物股票购买,丸美生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丸美生物(603983)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丸美生物(603983)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}